# Enteric Coating Enhances the Biopharmaceutical Performance of a Silica–Lipid Formulation of Abiraterone Acetate

**Authors:** Ali Taheri, Ruba Almasri, Anthony Wignall, Felicia Feltrin, Kristen E. Bremmell, Paul Joyce, Clive A. Prestidge

PMC · DOI: 10.3390/pharmaceutics17101289 · Pharmaceutics · 2025-10-02

## TL;DR

Enteric coating improves drug absorption by preventing premature precipitation of a poorly water-soluble drug in the stomach.

## Contribution

Enteric coating with Eudragit L100-55 enhances the biopharmaceutical performance of silica–lipid formulations of weakly basic drugs.

## Key findings

- Enteric-coated formulation showed over 50% greater drug presence in the aqueous phase during intestinal digestion.
- Enteric-coated formulation increased systemic drug exposure by 2.6-fold in rats compared to non-coated formulation.

## Abstract

Background/Objectives: Lipid-based formulations are widely used to enhance the oral bioavailability of poorly water-soluble drugs. However, for weakly basic drugs with higher solubility under acidic conditions, precipitation and recrystallisation after gastric emptying can compromise a formulation’s ability to maintain the drug in a solubilised, absorbable state. To address this, we evaluated an enteric coating strategy to preserve the biopharmaceutical performance of a silica-solidified lipid-based formulation. Methods and Results: The model weakly basic BCS Class IV drug, abiraterone acetate, was loaded into a lipid-based formulation and solidified using mesoporous silica nanoparticles. In an in vitro lipolysis model, introducing the formulation only after the onset of the intestinal phase led to lower precipitation and over 50% greater drug presence in the aqueous phase compared to a two-stage gastric–intestinal digestion. In an in vivo pharmacokinetic study in Sprague Dawley rats, the silica–lipid formulation (6 mg/kg), delivered in gelatine minicapsules enteric-coated with Eudragit L100-55, resulted in a 2.6-fold higher systemic exposure compared to the non-coated formulation (p < 0.0001). Conclusions: These findings support the use of enteric coating for lipid-based formulations and silica nanoparticles containing weakly basic drugs as a strategy to maintain formulation integrity until reaching the small intestine.

## Linked entities

- **Chemicals:** abiraterone acetate (PubChem CID 9821849)

## Full-text entities

- **Chemicals:** Lipid (MESH:D008055), Silica-Lipid (-), silica (MESH:D012822), Eudragit L100-55 (MESH:C446821), Abiraterone Acetate (MESH:D000069501)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12566802/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12566802/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12566802/full.md

---
Source: https://tomesphere.com/paper/PMC12566802